Бесплатная главастраницы PDF 37–44

1. Патофизиология ЦСХР

В оригинале: 1 Pathophysiology of CSCR

Из книги «Центральная серозная хориоретинопатия». Перевод главы на русский открыт всем без входа и подписки.

Содержание главы
  1. Глава 1. Патофизиология ЦСХРП
  2. Введение
  3. Механизмы изменений сосудистой оболочки: пахихориоидея
  4. Пигментный эпителий сетчатки (ПЭС)
  5. Изменения нейроретины
  6. Исходное место поражения
  7. Генетическая гипотеза
  8. Гипотеза минералокортикоидного пути
  9. Каковы последствия активации пути МР в ПЭС и сосудистой оболочке?
  10. Есть ли доказательства активации пути МР при ЦСХРП?
  11. Заключение

Литература

  1. 1. Prünte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol. 1996;121(1):26–34.
  2. 2. Reiner A, Fitzgerald MEC, Del Mar N, Li C. Neural control of choroidal blood flow. Prog Retin Eye Res. 2018;64:96–130.
  3. 3. Tomasso L, Benatti L, Rabiolo A, et al. Retinal vessels functionality in eyes with central serous chorioretinopathy. Br J Ophthalmol. 2018;102(2):210–214.
  4. 4. Estruch Fajardo IM, Rodríguez Villalón CH, Dorado García A, Gómez Echevarría AH. Central serous choroiditis. Possible allergic etiopathogenesis: Preliminary report. Allergol Immunopathol (Madr). 1985;13(3):249–257.
  5. 5. Bousquet E, Zhao M, Thillaye-Goldenberg B, et al. Choroidal mast cells in retinal pathology: a potential target for intervention. Am J Pathol. 2015;185(8):2083–2095.
  6. 6. Zhao M, Célérier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012;122(7):2672–2679.
  7. 7. Michael JC, Pak J, Pulido J, de Venecia G. Central serous chorioretinopathy associated with administration of sympathomimetic agents. Am J Ophthalmol. 2003;136(1):182–185.
  8. 8. DuPont JJ, Jaffe IZ. 30 Years of the mineralocorticoid receptor: the role of the mineralocorticoid receptor in the vasculature. J Endocrinol. 2017;234(1):T67–T82.
  9. 9. Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina Phila PA. 2015;35(1):1–9.
  10. 10. Muñoz-Durango N, Vecchiola A, Gonzalez-Gomez LM, et al. Modulation of immunity and inflammation by the mineralocorticoid receptor and aldosterone. Biomed Res Int. 2015;2015:652738.
  11. 11. Moss ME, Jaffe IZ. Mineralocorticoid receptors in the pathophysiology of vascular inflammation and atherosclerosis. Front Endocrinol. 2015;6:153.
  12. 12. Venkatesh P, Takkar B, Temkar S. Clinical manifestations of pachychoroid may be secondary to pachysclera and increased scleral rigidity. Med Hypotheses. 2018;113:72–73.
  13. 13. Daruich A, Matet A, Dirani A, et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015;48:82–118.
  14. 14. Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. Eye Lond Engl. 2018.
  15. 15. Negi A, Marmor MF. Mechanisms of subretinal fluid resorption in the cat eye. Invest Ophthalmol Vis Sci. 1986;27(11):1560–1563.
  16. 16. Wang C, Cao G-F, Jiang Q, Yao J. TNF-α promotes human retinal pigment epithelial (RPE) cell migration by inducing matrix metallopeptidase 9 (MMP-9) expression through activation of Akt/mTORC1 signaling. Biochem Biophys Res Commun. 2012;425(1):33–38.
  17. 17. Lin H-Y, Chen Y-S, Wang K, Chien H-W, Hsieh Y-H, Yang S-F. Fisetin inhibits epidermal growth factor-induced migration of ARPE-19 cells by suppression of AKT activation and Sp1-dependent MMP-9 expression. Mol Vis. 2017;23:900–910.
  18. 18. Gilet A, Zou F, Boumenir M, et al. Aldosterone up-regulates MMP-9 and MMP-9/NGAL expression in human neutrophils through p38, ERK1/2 and PI3K pathways. Exp Cell Res. 2015;331(1):152–163.
  19. 19. Tarjus A, Martínez-Martínez E, Amador C, et al. Neutrophil gelatinase-associated lipocalin, a novel mineralocorticoid biotarget, mediates vascular profibrotic effects of mineralocorticoids. Hypertension. 2015;66(1):158–166.
  20. 20. Kim YY, Flaxel CJ. Factors influencing the visual acuity of chronic central serous chorioretinopathy. Korean J Ophthalmol. 2011;25(2):90–97.
  21. 21. Ersoz MG, Karacorlu M, Arf S, Hocaoglu M, Sayman Muslubas I. Outer nuclear layer thinning in pachychoroid pigment epitheliopathy. Retina Phila PA. 2018;38(5):957–961.
  22. 22. Ten Berge JCEM, van Dijk EHC, Schreurs MWJ, Vermeer J, Boon CJF, Rothova A. Antiretinal antibodies in central serous chorioretinopathy: prevalence and clinical implications. Acta Ophthalmol. 2018;96(1):56–62.
  23. 23. Hussain AA, Lee Y, Zhang J-J, Marshall J. Characterization of the gelatinase system of the laminar human optic nerve, and surrounding annulus of Bruch’s membrane, choroid, and sclera. Invest Ophthalmol Vis Sci. 2014;55(4):2358–2364.
  24. 24. Hussain AA, Lee Y, Zhang J-J, Marshall J. Disturbed matrix metalloproteinase activity of Bruch’s membrane in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52(7):4459–4466.